ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

New or ReOpened Trials
No Trials Currently Available

JUST IN TIME TRIALS (JIT)

AML	ANAL	ALL
APL	BILIARY	BLADDER-UROTHELIAL
BRAIN	BREAST/ GYN	CANCER CONTROL
CLL	CML	COLON-RECTAL
ESOPHAGEAL - GASTRIC	HEAD & NECK	LYMPHOMA
MDS/MPN	MELANOMA	MERKEL
MOLECULAR STUDIES	MULTIPLE MYELOMA	NEUROENDOCRINE
NSCLC	PANCREATIC	PROSTATE
RADIATION TRIALS	RENAL CELL	SMALL CELL LUNG CANCER

Updated 4.12.23

RADIATION LOCATIONS:
OSF Glen Oak - OSF main hospital
OSF Route 91 (attached to Illinois CancerCare)
UPHM - Unity Point Health Methodist (NOW Carle Health Greater Peoria)
Galesburg - Western Illinois Cancer Treatment Center
SJMC - St Joseph Medical Center

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

MENU

APRIL 2023

JUST IN TIME (JIT) *TRIALS*	***Contact Disease Specific Navigator**
Multi-Disease Site: Advanced/Metastatic Solid Tumors	
RAIN-3202	A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors
ALL	
EA9213	A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)
Biliary	
EA2187	*Temporarily closed* Phase II study of Pevonedistat in Combincatoin with Carbo and paclitaxel in advanced intrahepatic cholangiocarcinoma.
Endometrial	
GY026	A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
Genitourinary - Rare	
A031702	Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors *(temp closed cohorts - small cell carcinoma/neuroendorine & adenocarcinoma of bladder, penile, and misc GU tract variants, renal medullary carcinoma, and rare GU)*
Head & Neck	
EA3191	A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
HN010	A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer
Neuroendocrine	

S2104	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Pancreas	
S2104	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Rectal	
EA2201	**(RT at Glen Oak, UPHM, Galesburg)** A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Renal Cell Carcinoma	
S2200	A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)
Skin	
A091802	Phase II randomized Trial of Avelumab plus cetuximab versus avelumab alone in advanced cutaneous Squamous cell carcinoma of skin

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

AML

Navigator - Heather x3661

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

ANAL

Navigator - Carrie x3621

EA2176 SCHEMA	A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
EA2182	**(RT at Carle and Glen Oak)** A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

APL

Navigator - Heather x3661

There are no trials available at this time

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

ACUTE LYMPHOBLASTIC LEUKEMIA

Navigator - Heather x3661

EA9213 - JIT Trial	A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

BILIARY

Navigator - Carrie x3621

EA9213 - JIT Trial	Temporatily closed | Phase II stud of Pevonedistat in Combincatoin with Carbo and Paclitaxel in advanced intrahepatic cholangiocarcinoma.

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

BLADDER / UROTHELIAL

Navigator - Carrie x3621

ADJUVANT / NEOADJUVANT	
EA8185	**(RT pending at Glen Oak & Rt-91)** Phase 2 Study of Bladder-Sparing Chemoradiation With MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)
S1806 SCHEMA	**(RT at Glen Oak, SJMC, Carle and Galesburg)** Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
S2011 SCHEMA	Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP TRIAL
METASTATIC	
A032001 SCHEMA	Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer
A032002 SCHEMA	**Temporarily Closed (RT at Glen Oak)** Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

BRAIN

Navigator - Carrie x3621

A071702 SCHEMA	A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
BN011 SCHEMA	**(RT credentialing pending)** A Phase III Trial of Gleostine® (Lomustine)-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
N0577	**(RT at Glen Oak, RT 91, and Carle)** Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

BREAST

Navigator - Angie x3613

DCIS	
No trials at this time	
NEO/ADJUVANT TREATMENT	
S1706*	**Not Actively Screeening - Contact Navigator -** A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (All biomarker subgroups eligible) |***JIT TRIAL - expect 1 week delay to consent pt**
Neo/Adjuvant - HER2 Positive	
A011801	The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
EA1181	Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response (CompassHER2-pCR) *(Closed to Her2+/ER+ w/ tumor 2.1-3cm and node negative)*
Neo/Adjuvant - Hormone Receptor Positive / HER2 Negative	
BR007 SCHEMA	**(RT at Galesburg, Glen Oak, Rt 91, Carle, SJMC)** Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
JSJ-MC-JZLH / EMBER-4	**Coming Apr/May 2023! (Peoria, Bloomington, Galesburg, Pekin, Washington, Ottawa, Peru)** A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
Neo/Adjuvant - Triple Negative *(no trials at this time)*	
METASTATIC TREATMENT	
Metastatic - HER2 Positive *(no trials at this time)*	
Metastatic - Hormone Receptor Positive / HER2 Negative	
S1703	Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer

S2007	**Not Actively Screening - contact Navigator**- A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
Metastatic - Triple Negative *(no trials at this time)*	
SURGERY / RADIATION ONLY	
MA.39	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer ***(RT: Glen Oak and UPHM)***
CANCER CONTROL (Breast only)	
A211901 SCHEMA	**Not Actively Screening - Contact Navigator** | Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
A212102 SCHEMA	**(Peoria, BLM, Canton, Gburg, Pekin, Peru, Ottawa, Wash)** Blinded Reference Set for Multicancer Early Detection Blood Tests *(healthy cohort closed)*
A222004 SCHEMA	**Not Actively Screening - Contact Navigator** | A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
EAQ202 SCHEMA	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials *(breast, leukemia, and lymphoma cohorts closed to accrual)*
S2010 SCHEMA	A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
S2108CD SCHEMA	**(Peoria, Bloomington, Galesburg, Canton, Ottawa)** A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
S1912CD SCHEMA	**Not Actively Screening - Contact Navigator** | A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
S2013 SCHEMA	**(Peoria, Bloomington, Galesburg, Pekin, Washington**) Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study **(I-CHECKIT)**
URCC 16070	Treatment of Refractory Nausea- for breast cancer patients.
URCC-18007	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue- *at least 2 months out from surgery/tx/radiation*
URCC 19185 SCHEMA	**Not Actively Screening - Contact Navigator** | **(Peoria, Bloomington, Canton, Galesburg, Pekin, Washington)** Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)

URCC 21038 SCHEMA	**(Peoria, Bloomington, Canton, Galesburg, Pekin, Washington)** Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
WF-1901 SCHEMA	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

GYNECOLOGICAL

Navigator - Angie x3613

NRG - GY023 SCHEMA	**Temporarily Closed** A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor (Durvalumab) MEDI4736 in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or (Durvalumab) MEDI4736 and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

Navigators - Courtney x3660
Erica x3626
Kelsey x 3618

CANCER CONTROL

MULTI-DISEASE SITES

A211901 SCHEMA	Not Actively Screening - Contact Navigator | Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
A212102 SCHEMA	**(Peoria, BLM, Canton, Gburg, Pekin, Peru, Ottawa, Wash)** Blinded Reference Set for Multicancer Early Detection Blood Tests *(healthy cohort closed)*
A222004 SCHEMA	Not Actively Screening - Contact Navigator | A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
EAQ202 SCHEMA	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials *(breast, leukemia, and lymphoma cohorts closed to accrual)*
S1912CD SCHEMA	Not Actively Screening - Contact Navigator | A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
S2013 SCHEMA	**(Peoria, Bloomington, Galesburg, Pekin, Washington)** Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study **(I-CHECKIT)**
S2108CD SCHEMA	**(Peoria, Bloomington, Galesburg, Canton, Ottawa)** A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
URCC-18007	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - *at least 2 months out from surgery/tx/radiation*
URCC 19185 SCHEMA	Not Actively Screening - Contact Navigator | **(Peoria, Bloomington, Canton, Galesburg, Pekin, Washington)** Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
URCC 21038 SCHEMA	**(Peoria, Bloomington, Canton, Galesburg, Pekin, Washington)** Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
WF-1901 SCHEMA	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

BREAST

S2010 SCHEMA	A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
URCC 16070	Treatment of Refractory Nausea- for breast cancer patients.

LUNG

JOVIALITY 23289	**(Peoria only) Safety and Acceptability: Virtual Reality for Psychotherapy Delivery in Lung Cancer Patients of Illinois CancerCare**

COLORECTAL	
WF-1806	(M&M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer
BRAIN	
WF-1801	A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
REGISTRY	**Navigator - Heather 243-3661**
Connect Myeloid SCHEMA	The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. *(enrolling cohorts : low risk MDS, Treated MF, Treated MF cytopenias - includes CMML, aCML, MDS/MPN-RS-T, MDS/MPN unclassifiable)*
NHLBI-MDS	**(Peoria, Bloomington and Galesburg only)** -The National Myelodysplastic Syndromes (MDS) Study

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

Navigator - Ashton x3611
Carrie x3621

CARCINOID

A021602	Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo In Patients With Advanced Neruodenocrine Tumors After progression on Prior Therapy (CABINET)

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

CLL

Navigator - Heather x3661

no trials at this time

1st Line

2nd Line, 3rd Line, etc.

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

CML

Navigator - Heather x3661

Connect Myeloid SCHEMA	The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. *(enrolling cohorts : newly diagnosed low risk MDS, Treated low risk MDS, Treated MF, Treated MF cytopenias - includes CMML, aCML, MDS/MPN-RS-T, MDS/MPN unclassifiable)*

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

COLON / RECTAL

Navigator - Carrie x3621

	Adjuvant
C-14	**(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington)** Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using A Circulating Tumor DNA Assay To Detect Minimal Residual Disease **(CORRECT-MRD II)**
EA2201 - JIT	**(RT at Glen Oak, Carle, Galesburg)** A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
GI005	Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
GI008 SCHEMA	Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
	Metastatic
S2107 SCHEMA	Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
	CANCER CONTROL (Colorectal only)
A211901 SCHEMA	**Not Actively Screening - Contact Navigator** | Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
A212102 SCHEMA	Blinded Reference Set for Multicancer Early Detection Blood Tests *(healthy cohort closed)*
A222004 SCHEMA	**Not Actively Screening - Contact Navigator** | A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
EAQ202 SCHEMA	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials *(breast, leukemia, and lymphoma cohorts closed to accrual)*
A212102 SCHEMA	**(Peoria, BLM, Canton, Gburg, Pekin, Peru, Ottawa, Wash)** Blinded Reference Set for Multicancer Early Detection Blood Tests
S1912CD SCHEMA	**Not Actively Screening - Contact Navigator** | A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
S2013 SCHEMA	**(Peoria, Bloomington, Galesburg, Pekin, Washington)** Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study **(I-CHECKIT)**

S2108CD SCHEMA	**(Peoria, Bloomington, Galesburg, Canton, Ottawa)** A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
URCC-18007	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - *at least 2 months out from surgery/tx/radiation*
URCC 19185 SCHEMA	**Not Actively Screening - Contact Navigator** | **(Peoria, Bloomington, Canton, Galesburg, Pekin, Washington)** Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
URCC 21038 SCHEMA	**(Peoria, Bloomington, Canton, Galesburg, Pekin, Washington)** Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
WF-1901 SCHEMA	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)
WF-1806	(M&M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

ESOPHAGEAL- GASTRIC

Navigator - Carrie x3621

A022102 SCHEMA	Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

HEAD & NECK

Navigator - Ashton x3611

EA3161 SCHEMA	**(RT at Glen Oak, Carle, Galesburg)** A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
EA3191 - JIT	A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
HN005	**Temporarily Closed (RT at Galesburg, Glen Oak)** A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
HN009 SCHEMA	**(RT at Carle)** Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
HN010 - JIT Trial	A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer
S2101 SCHEMA	Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

Navigator - Heather x3661

LYMPHOMA

HL
No HL trials at this time
NHL

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

MDS/MPN

Navigator - Heather x3661

Connect Myeloid SCHEMA	The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. *(enrolling cohorts : newly diagnosed low risk MDS, Treated low risk-MDS, Treated MF, Treated MF cytopenias - includes CMML, aCML, MDS/MPN-RS-T, MDS/MPN unclassifiable)*
NHLBI-MDS	**(Peoria, Bloomington and Galesburg only)** -The National Myelodysplastic Syndromes (MDS) Study

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

MELANOMA

Navigator - Carrie x3621

S2101 SCHEMA	Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

MERKEL

Navigator - Carrie x3621

EA6174	**Temporarily Closed (RT at Glen Oak, Carle, Galesburg)** A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

MOLECULAR STUDIES

***Contact Disease Specifc Navigator**

A151804	Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
S1823 SCHEMA	A Study of miRNA 371 in Patients With Germ Cell Tumor *(closed to high risk pts or pts on chemo for testicular cancer)*
TP-CA-003 (Sculptor)	**(Peoria, Blm, Canton, Gburg, Ottawa, Pekin, Peru, Washington)** A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays (TEMPUS)
TPX-0005-01 (TRIDENT-1) SCHEMA	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with **Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements** (TRIDENT-1)

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

MULTIPLE MYELOMA

Navigator - Heather x3661

EAA173 SCHEMA	Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
S1803	**Temporarily Closed** | Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

NEUROENDOCRINE

Navigator - Carrie x3621

A021602	Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo In Patients With Advanced Neruodenocrine Tumors After progression on Prior Therapy (CABINET)
A021804	A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
S2104 - JIT Trial	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

NSCLC

Navigator - Ashton x3611

ADJUVANT / NEOADJUVANT

A081801 SCHEMA	Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ALCHEMIST substudy- *Must be enrolled on ALCHEMIST and this substudy prior to start of tx).*
A151216	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial **(ALCHEMIST)**.
EA5181 SCHEMA	**(RT at Glen Oak, Carle and Galesburg)** Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC **(credentialing pending at Rt-91)**
S1914	**(RT at Glen Oak, Carle, Galesburg)** Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

METASTATIC - 1st Line

EA5182 SCHEMA	Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
GS-US-626-6216 (STAR-121) SCHEMA	**(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington)** A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
MK 7684A-003 SCHEMA	**Screening by referral only (Peoria only)** A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer
S2302 (Pragmatica) SCHEMA	**NEW!** A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer **(Pragmatica-Lung)**

METASTATIC - 2nd/3rd Line

EA5162 SCHEMA	Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
LUNGMAP	A Master Protocol To Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated NSCLC. (**SUB-STUDIES: S1800D (CLOSED)** - *A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy;* **S1900E** - *A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer)* ; **S1900F**- A Randomized Phase II Study of Carboplatin and Pemetrexed w/ or w/o Selpercatinib in Participants With Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy)

CANCER CONTROL (NSCLC Only)

A211901 SCHEMA	**Not Actively Screening - Contact Navigator** | Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

A212102 SCHEMA	**(Peoria, BLM, Canton, Gburg, Pekin, Peru, Ottawa, Wash)** Blinded Reference Set for Multicancer Early Detection Blood Tests *(healthy cohort closed)*
A222004 SCHEMA	**Not Actively Screening - Contact Navigator** | A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
EAQ202 SCHEMA	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials *(breast, leukemia, lymphoma cohorts closed to accrual)*
JOVIALITY 23289	**NEW! (Peoria only) Safety and Acceptability: Virtual Reality for Psychotherapy Delivery in Lung Cancer Patients of Illinois CancerCare**
S2108CD SCHEMA	**(Peoria, Bloomington, Galesburg, Canton, Ottawa)** A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
S1912CD SCHEMA	**Not Actively Screening - Contact Navigator** | A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention **(CREDIT)**
S2013 SCHEMA	**(Peoria, Bloomington, Galesburg, Pekin, Washington)** Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study **(I-CHECKIT)**
URCC-18007	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - *at least 2 months out from surgery/tx/radiation*
URCC 19185 SCHEMA	**Not Actively Screening - Contact Navigator | (Peoria, Bloomington, Canton, Galesburg, Pekin, Washington)** Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
URCC 21038 SCHEMA	**(Peoria, Bloomington, Canton, Galesburg, Pekin, Washington)** Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
WF-1901 SCHEMA	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

PANCREATIC

Navigator - Carrie x3621

EA2186 SCHEMA	A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
EA2192 SCHEMA	A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (APOLLO)
S2001 SCHEMA	Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
S2104 - JIT Trial	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

PROSTATE

Navigator - Carrie x3621

	ADJUVANT
GU008 SCHEMA	**(RT at Glen Oak, Carle)** Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): *Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy*
GU009 SCHEMA	**(RT at Glen Oak, Galesburg, Carle, Rt 91)** Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation **(PREDICT-RT*)**
GU010 SCHEMA	**(RT at Carle)** Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
	METASTATIC
A032101 SCHEMA	A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM
C2321001 SCHEMA	**(Peoria only)** A Phase I Dose Escalation and Expanded Cohort Study of PF-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL)
A031902 / CASPAR SCHEMA	**Temporarily Suspended** |A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

GU011 SCHEMA	**(RT at Glen Oak and Carle)** A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
S1802	**(RT at Glen Oak, SJMC & Carle)** Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

RENAL CELL

Navigator - Carrie x3621

A031704 SCHEMA	PD-Inhibitor (nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
MK 6482-011 SCHEMA	**(Peoria, Bloomington, Galesburg, Pekin)** An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
S2200 SCHEMA	A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

RADIATION TRIALS

Navigator - Jessica x3615

CANCER CONTROL	
WF-1801	A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
ANAL	
EA2182	**(Carle and Glen Oak)** A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
BLADDER	
A032002 SCHEMA	**Temporarily Closed (RT at Glen Oak)** Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)
EA8185	**(RT pending at Glen Oak & Rt-91)** Phase 2 Study of Bladder-Sparing Chemoradiation With MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)
S1806 SCHEMA	**(Glen Oak, SJMC, Carle and Galesburg)** Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
BRAIN	
N0577	**(Glen Oak, RT 91, and Carle)** Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
BRAIN METS	
CCTG CE.7	**(Glen Oak)-** A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases
BREAST	
BR007 SCHEMA	**(Galesburg, Glen Oak, Rt 91, Carle, SJMC)** Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

MA.39	**(Glen Oak)** Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
HEAD & NECK	
EA3161 SCHEMA	**(Glen Oak, Carle, Galeburg)** A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
HN005	**Temporarily Closed (Galesburg, Glen Oak)** A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
HN009 SCHEMA	**(RT at Carle)** Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
MERKEL CELL	
EA6174	**Temporarily Closing 3.31.23 (Glen Oak, Carle and Galesburg)** A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
NSCLC	
EA5181 SCHEMA	**(Carle, Glen Oak and Galesburg)** Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC **(credentialing pending at Rt 91)**
S1914	**(Glen Oak, Carle, Galesburg)** Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
PROSTATE	
GU008 SCHEMA	**(RT at Glen Oak, Carle)** Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): *Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy*
GU009 SCHEMA	**(RT at Glen Oak, Galesburg, Carle, Rt 91)** Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation **(PREDICT-RT*)**

GU010 SCHEMA	**(RT at Carle)** Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
GU011 SCHEMA	**(RT at Glen Oak & Carle)** A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
S1802	**(Glen Oak, SJMC & Carle)** Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
WF-1802	**(Glen Oak, Rt-91, Carle, Galesburg)** Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)
SCLC	
NRG CC009 SCHEMA	**(Glen Oak, Carle)** - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
S1827	**(Glen Oak, Galesburg, SJMC**) A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer

ILLINOIS CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

APRIL 2023

MENU

SMALL CELL LUNG CANCER

Navigator - Ashton x3611

NRG CC009 SCHEMA	**(RT at Glen Oak, Carle)** - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
GO43104 SCHEMA	**(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington)** A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin In Combination With Atezolizumab Compared With Atezolizumab As Maintenance Therapy In Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Followiing First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab
S1827	**(RT at Glen Oak, Galesburg, SJMC)** A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer
TP-CA-003 (Sculptor)	**(Peoria, Blm, Canton, Gburg, Ottawa, Pekin, Peru, Washington)** A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays (TEMPUS)

C2321001 SCHEMA

Contact Disease Specific Navigator

MENU



*50-70% down modulation of H3K27me3

US-VEN-207 (ULTRA-V) Schema
Navigator - Heather x3661

MENU

FIGURE 2: PHASE 3 STUDY DESIGN



*BTK-refractory defined as disease progression while on, or within 6 months of the last dose of a BTK inhibitor (e.g., ibrutinib, acalabrutinib, etc)

MK 6482-011 Schema
Navigator - Carrie x3621

MENU



TPX-0005-01 Schema
Contact Disease Site Specific Navigator

MENU

Figure 2. Schema of TPX-0005-01 Study



EA5181 SCHEMA

Navigator - Ashton x3611

MENU

Schema



A081801 SCHEMA
Navigator - Ashton x3611

MENU

Schema: 1 cycle = 21 days



S1823 SCHEMA
Navigator - Carrie x3621

MENU

SCHEMA



* Patients and providers will not have knowledge of the results of the miRNA 371 analysis.

EA8185
Navigator -Carrie x3621

MENU

Schema



EA2176
Navigator -Carrie x3621

MENU



1. Randomization is 1:2 (A:B).
2. For this protocol, all patients, including those who discontinue protocol therapy early, will be followed for response until disease progression, even if non-protocol therapy is initiated, and for survival every 3 months for two years from the date of randomization. All patients must also be followed through completion of all protocol therapy.



BICR=blinded independent central review; DMC=Data Monitoring Committee; IMDC=International Metastatic Renal Cell Carcinoma Database Consortium; QD=once daily; RCC=renal cell carcinoma; ROW=rest of world; TKI=tyrosine kinase inhibitor; US=United States; VEGF=vascular endothelial growth factor.

WF-1901
Navigator -Courtney x3660

MENU



EA3161
Navigator -Ashton x3611

MENU

Schema



Accrual Goal: 744

1. Submit tissue for PD-L1 testing.
2. Cycle length = 28 days
3. Patients who were randomized to observation will be offered the option to cross over if they have clearly documented progression by the RECIST criteria and tissue-proven progression within 12 months from the end of cisplatin/radiation therapy.

EA5182
Navigator -Ashton x3611

MENU

Schema



Accrual Goal = 300 patients
Cycle = 3 weeks (21 days)

Schema

PK Substudy (Dose Finding Portion) Only



Phase III (Double-Blinded, Placebo-Controlled) Portion



For all patients, treatment is to continue until disease progression or unacceptable adverse event. Patients will be followed for 5 years or until death, whichever comes first.

Please refer to the full protocol text for a complete description of the eligibility criteria and treatment plan.

S1806
Navigator -Carrie x3621

MENU



A031704
Navigator -Carrie x3621

MENU

Schema

1 cycle = 28 days



GU008
Navigator -Carrie x3621

MENU



NRG-CC009
Navigator -Jessica x3615

MENU

NRG-CC009
SCHEMA

STEP 1 REGISTRATION

↓

STEP 2 REGISTRATION/RANDOMIZATION

Baseline neurocognitive function (NCF) tests: HVLT-R, TMT, COWA (*required*)
Note: NCF testing scores must be uploaded into Rave prior to Step 2 Registration and can be uploaded at the time of Step 1 Registration

STRATIFY
Disease-Specific Graded Prognostic Assessment (DS-GPA)[2]:
1. 0.5-2.0
2. 2.5-4.0

Prior exposure to NCF testing on SWOG S1827[3]:
1. Yes
2. No

RANDOMIZE[1]

↓ ↓

Arm 1	**Arm 2**
Stereotactic radiosurgery (SRS)	Whole brain radiotherapy with hippocampal avoidance (HA-WBRT)+ Memantine

[1]Randomization is 1:1

GU009
Navigator -Carrie x3621

MENU

NRG-GU009
SCHEMA

STEP 1 REGISTRATION
Completion of Step 1 eligibility checklist in OPEN and then submission of tissue for Decipher analysis
Note: Decipher analysis results must be completed before **Step 2 randomization** can occur. If Decipher results have already been obtained, in lieu of tissue, after completion of Step 1 eligibility checklist in OPEN, the original Decipher report must be submitted to Decipher Biosciences for validation (see Decipher Analysis information at the end of section 3.0).

STEP 2 RANDOMIZATION
Decipher ≤ 0.85

DE-INTENSIFICATION STUDY
STRATIFY

- Decipher Score (Low/Int v High*)
- Boost type (EBRT vs. Brachy)
- Pelvic Treatment (Yes/No)
- ACE-27 Comorbidity (0/1 vs 2/3)**

RANDOMIZE 1:1

Arm 1
RT
+
24 mos ADT

Arm 2
RT
+
12 mos ADT

STEP 2 RANDOMIZATION
Decipher > 0.85 or Node Positive

INTENSIFICATION STUDY
STRATIFY

- Boost type (EBRT vs. Brachy)
- Pelvic Treatment (Yes/No)
- Nodal Status (Positive/Negative)

RANDOMIZE 1:1

Arm 3
RT
+
24 mos ADT

Arm 4
RT
+
24 mos ADT
+24 mos Apalutamide

* Low/Intermediate = Decipher < 0.6 and High = Decipher 0.6-0.85
** http://comogram.org/assets/files/ace-27_ctr_ver_rtog_web.pdf
Note: A radiation treatment approach change post registration involving the pelvic lymph node treatment or prostate boost type stratification factors will result in a protocol deviation.
RT = radiation therapy; ADT = androgen deprivation therapy

MK 7684A-003
Navigator -Ashton x3611

MENU



BR007
Navigator -Angie Earles x3613

MENU



NRG-GY023
Navigator -Angie Earles x3613

MENU



*Non-platinum single agent chemotherapy includes weekly paclitaxel, topotecan or pegylated liposomal doxorubicin (PLD). There can be no deviance from the prescribed regimens, e.g. addition of bevacizumab or other agents.

Randomization is 1:2:2:2

S1912CD
Navigator -Kelsey Fay x3618

MENU

SCHEMA

Patient and spouse caregiver

Completion of baseline forms



In order to participate, CCD Research sites must complete the **S1912CD** Site Implementation Survey and upload the completion certificate to the CTSU Regulatory Portal as described in Section 13.4.
* Consumer Education and Training Services (CENTS)
** Patient Advocate Foundation (PAF)

GO43104
Navigator -Ashton Todd 3611

MENU



S2013
Navigator - Kelsey Fay x3618

MENU

SCHEMA



S2011
Navigator -Carrie Geoffroy x3621

MENU



A222004
Navigator -Kelsey Fay x3618

MENU



Treatment will continue for up to 4 weeks, unless the patient declines therapy or has unacceptable adverse events.

EAQ202
Navigator -Courtney Brown x3660

MENU

Schema



Eligibility:	**Randomization:**	**Domain Rank:**
-Age 18 to 39 -Within 12 weeks of diagnosis -Performance Status 0-3 -Any stage of cancer -Favorable prognosis	Stratified by sex, race, ethnicity, and age (emerging adults 18-25-year-old vs young adults 26-39-year-old)	Participant Ranks Domain by personal priority at each time point **Fixed PRO:** PROMIS Global, PROMIS standard AYA 5 domains, Common Items **Choice PRO:** PROMIS Global, 5 ranked AYA domains, Common Items

Accrual Goal = 400

GU010
Navigator -Jessica Jones x3615

MENU

SCHEMA



*For Escalated RT boost definition see Section 5.2 Establishing Treatment Approaches
**Randomization is 1:1
RT = radiation therapy; SBRT=stereotactic body radiotherapy; ADT =androgen deprivation therapy

BN011
Navigator -Carrie Geoffroy x3621

MENU

NRG-BN011
SCHEMA

STEP 1 REGISTRATION

Central Pathology Review for confirmation of glioblastoma (GBM) histology and of methylated MGMT promotor status

NOTE: Tumor tissue must be received and central review confirmation completed before STEP 2 registration can occur.*

↓

STEP 2 REGISTRATION

STRATIFY

- Recursive partitioning analysis (RPA) (III vs IV vs V)
- Intent to use tumor treating fields (Optune) (yes vs no)

RANDOMIZE (1:1)

Arm 1	**Arm 2**
Radiation Therapy with Concomitant and Adjuvant Temozolomide	Radiation Therapy with Concomitant and Adjuvant Lomustine and Temozolomide

See Section 5.1 for agent treatment details and Section 5.2 for radiation therapy details.

*Patients with unmethylated MGMT may be considered for enrollment on NRG-BN007. Please see Section 10.2 for additional information.

A032002
Navigator -Carrie Geoffroy x3621

MENU

Alliance A032002

Schema

1 Cycle = 21 Days



Treatment is to continue until disease progression or unacceptable adverse event. Patients will be followed for 3 years or until death, whichever comes first.

Schema



* Target quit date will be 8 weeks following enrollment.
** NCI's Smokefree.TXT messages will start 2 weeks before quit date and extend for 4 weeks after quit date.
*** Quit date must be within 8 weeks of receiving the *Clearing The Air* cessation booklet

Please refer to the full protocol text for a complete description of the eligibility criteria and intervention plan.

NSABP C-14
Navigator -Carrie x3621

MENU



GU011
Navigator -Carrie x3621

MENU

NRG-GU011
SCHEMA

Recurrent Oligometastatic Prostate Cancer (detected by PET) after RT to Prostate or Radical Prostatectomy +/- Post-Operative Radiotherapy

STRATIFY

- Extrapelvic node(s) only vs Bone +/- node(s) [pelvic/extrapelvic]
- PSA Doubling Time <12 mos vs ≥ 12mos
- Fluciclovine PET vs PSMA PET

RANDOMIZE*

↓ ↓

Arm 1	**Arm 2**
SABR + blinded placebo** for 6 months	SABR + blinded relugolix** for 6 months

*Randomization is 1:1

** Monitor according to Test Schedule; see Sections 4.2, 4.3, and 5.3.1 for progression. Salvage ADT should be delayed until metastatic progression by conventional imaging.

A032001
Navigator -Carrie x3621

MENU

Schema

1 Cycle = 28 Days



*Randomization is to occur 3-10 weeks after last dose of 1st-line treatment

Stratification:

- Best response to 1st-line chemo (SD vs PR vs CR)
- Visceral metastases: present versus absent

Please refer to the full protocol text for a complete description of the eligibility criteria and treatment plan.

NRG GI008
Navigator -Carrie x3621

MENU

Figure 1.
NRG-GI008 SCHEMA



*Patients with completely resected stages II or IIIC colon cancer who are ctDNA +ve as determined by a Signatera™ ctDNA test performed outside of the trial through routine clinical care and who otherwise meet all eligibility criteria for Step 1-Registration are eligible for enrollment into Cohort B.

**Patients in Cohort A (Arm 2) who develop a ctDNA +ve assay during serial monitoring may transition to the ctDNA+ve cohort (Cohort B) and undergo a second randomization.

URCC 21038
Navigator -Erica x3626

MENU

STUDY SCHEMA

Screen patients scheduled to receive an FDA approved anti-PD-1/-L1 immune checkpoint inhibitor (ICI) for the first time, alone or in combination with co-treatments

Register and **consent** patients prior to the first infusion of ICIs

Baseline (A1): up to two weeks before the patient's first ICI infusion, collect:
- Clinical record and laboratory data
- Patient Reported Outcomes (PROs)
- Peripheral blood samples
- Saliva sample
- Tumor samples (if available)

During Treatment (A2): up to a week before the patient's second ICI infusion (usually 2-3 weeks after A1), collect:
- Clinical record and laboratory data
- Patient Reported Outcomes (PROs)
- Peripheral blood samples
- Saliva sample

6 Month Follow Up (A3): 6 months ± 1 month after the first ICI infusion, collect:
- Clinical record and laboratory data
- Patient Reported Outcomes (PROs)
- Peripheral blood samples

Annual Follow Up (A4+): 1 year ± 3 months after the first ICI infusion, and yearly thereafter until patient death or study end, collect:
- Clinical record and laboratory data
- Patient Reported Outcomes (PROs)
- Peripheral blood samples

At each infusion while the patient is on ICI treatment, collect Cancer Treatment, Toxicity and Response data

NRG- HN009
Navigator -Ashton x3611

MENU

For patients with oropharyngeal cancer (OPC) or cancer of unknown primary (CUP):
Local p16 determination by immunohistochemistry is required.

For patients with laryngeal and hypopharyngeal primaries:
Analysis of p16 status is **not required.**

↓

STRATIFY

- Zubrod (ECOG) performance status: 0 vs. 1
- Smoking status: ≤ 10 pack-year vs. > 10 pack-year history
- T stage: T0-3 vs. T4
- Age: ≤ 50 vs. > 50 years

RANDOMIZE (1:1 in each cohort)

↓

Non-OPC/p16-negative OPC Cohort

Arm 1: IMRT/IMPT + High-dose cisplatin Q 3 weeks

Arm 2: IMRT/IMPT + Low-dose cisplatin weekly

↓

p16-positive OPC/CUP Cohort

Arm 3: IMRT/IMPT + High-dose cisplatin Q 3 weeks

Arm 4: IMRT/IMPT + Low-dose cisplatin weekly

S2107 SCHEMA

Navigator - Carrie x3621

MENU



*** Proficient mismatch repair (pMMR)**
**** Microsatellite stable (*MSS*)**
*****An activating missense mutation in codon 600 of exon 15 B-Raf proto-oncogene (*BRAF*^{V600E})**
*******Treatment continues until participant meets one of the criteria listed in Section 7.7.***

A071702 SCHEMA

Navigator - Carrie x3621

MENU

* During Cycles 1-4, one cycle is defined as 3 weeks. Beginning at Cycle 5, one cycle is defined as 4 weeks.

Treatment is to continue until disease progression, unacceptable toxicity, or withdrawal of consent. Patients will be followed for survival and progression every 3 weeks during Cycle 1-4 and every 4 weeks after Cycle 5 until progression, and then for survival every 3 months until 3 years after registration or until death, whichever comes first.

A021602
Navigator -Carrie x3621

MENU

1 Cycle = 28 Days



A032101
Navigator -Carrie x3621

MENU

Schema



Treatment is re-initiated per the pre-specified triggers (PSA increase to ≥ 5 ng/ml, radiographic change [PD on CT/MRI imaging per modified RECIST 1.1 or PDu on bone scintigraphy per PCWG3], or symptoms attributable to prostate cancer). Subsequent management is per physician discretion. Patients undergo protocol assessments until a new treatment is initiated after the initial ARPI is permanently discontinued (i.e. at time to next treatment [TTNT]), and are subsequently followed until withdrawal of consent or death.

A212102
Navigator -Kelsey x3618

MENU



* Slot reservation required (see Section 4.3).

** For patients with a cancer diagnosis, biospecimens and data should be collected prior to any definitive therapy for the cancer.

S2108CD
Navigator -Courtney Brown x3660

MENU

SCHEMA



* A Recruitment Center is defined as an outpatient clinic, or group of clinics, belonging to the same NCORP or MU-NCORP, that will be contributing physician and patient participants to the study. Each clinic within the Recruitment Center must have a CTEP Site ID. All Recruitment Centers must have completed a **S2108CD** Recruitment Center Application and received approval for participation.

GS-US-626-6216 (STAR-121)
Navigator -Ashton Todd x3611

MENU



AUC = area under the curve; BICR = blinded independent central review; DOR = duration of response; ECOG = Eastern Cooperative Oncology Group; eDMC = external Data Monitoring Committee; NSCLC = non-small cell lung cancer; ORR = objective response rate; OS= overall survival; PD-L1 = programmed cell death ligand 1; PFS = progression-free survival; Q3W = every 3 weeks; QOL = quality of life; QW = weekly; R = randomized; TPS = tumor proportion score

*The first eDMC review is planned after a safety run-in period, defined as approximately 20 participants randomized in Group A completing at least 1 full study cycle.
**Zimberelimab, domvanalimab, and pembrolizumab are given Q3W for a maximum of 35 doses.
***Choice of chemotherapy is dependent on histology. Participants with nonsquamous histology will receive cisplatin 75 mg/m^2 or carboplatin AUC 5 with pemetrexed 500 mg/m^2 Q3W. Those with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m^2 Q3W or nab-paclitaxel 100 mg/m^2 QW. For participants with nonsquamous histology, pemetrexed 500 mg/m^2 Q3W is continued after 4 cycles of induction chemotherapy until PD or intolerable toxicities.



a. ICUS diagnosis: refers to the date of either (a) the most recent BM aspirate/biopsies, or (b) the date of the laboratory assessment documenting cytopenia(s) consistent with the severity and length of time required for an ICUS diagnosis
b. MDS Diagnosis: refers to the date of initial BM aspirate/biopsies for patients with classified risk of MDS.
c. AML Diagnosis: refers to the date of initial BM aspirate/biopsies or the date of initial peripheral blood sample that led to the suspected diagnosis (not the date of subsequent samples)
d. Diagnosis reports to be submitted for the Central Eligibility Review (CER) should include (not limited to) BM aspirate/biopsies report, cytogenetic report, peripheral laboratory results (including the percentage of blasts, if available), and any other laboratory results or reports that led to the diagnosis of MDS, ICUS or AML.

Figure 2: Study Schema: Treated MF[9] Cohort



Figure 3: Study Schema: Treated LR-MDS Cohort



EAA173
Navigator -Heather x3661

MENU



Accrual Goal: 288 patients with high-risk smoldering multiple myeloma.[5]
Cycle: 28 days

1. Peripheral blood stem cells for future transplants should be collected between cycles 4-6 of therapy. Therapy may be interrupted for up to 6 weeks to allow for PBSC collection. While collection following 4-6 weeks of therapy is strongly suggested, it is not required for protocol participation.
2. All patients, including those who discontinue protocol therapy early, will be followed for response until progression, even if non-protocol therapy is initiated, and for survival for 15 years from the date of randomization.
3. In patients with calculated (Cockroft-Gault) creatinine clearance of 30-59 ml/min, starting dose of lenalidomide should be reduced to 10 mg. If the clearance improves to ≥ 60 ml/min, the dose can be increased to 25 mg provided the patient has not experienced any of the toxicities that would require a dose reduction for lenalidomide.
4. Submission of pre-study specimens per patient consent.
5. Patients must be diagnosed within the past 12 months. See Section 3.2.2 for the definition of high-risk SMM.
6. Patients currently receiving IV daratumumab should cross over to SC daratumumab-hyaluronidase unless they do not tolerate daratumumab-hyaluronidase. Patients intolerant of SC daratumumab-hyaluronidase may remain on or cross over to IV daratumumab. Please refer to section 5.1.1 for daratumumab treatment details.
7. For patients receiving IV daratumumab, split-dosing schedule may be used for first IV infusion, and will consist of 8mg/kg given on Cycle 1, days 1 and 2 only

EA2186
Navigator -Carrie x3621

MENU



1. Patients will complete a comprehensive geriatric assessment and Quality of Life prior to starting treatment.

EA2192
Navigator -Carrie x3621

MENU



[1] One cycle = 4 weeks
[2] Olaparib is supplied in either 100 mg or 150 mg tablets

NOTE: Please note that when a patient has been successfully randomized, the confirmation of randomization will indicate that the patient is on Arm X. The patient will actually be randomized to Arm A or B, but as this is a double-blind trial, that information cannot be displayed.

S2001
Navigator -Carrie x3621

MENU



S2101
Navigator -Carrie x3621
Navigator - Ashton x3611

MENU



- TMB= tumor mutational burden; GEP = gene expression profiling for tumor inflammation score; WES = whole exome sequencing for tumor mutational burden
- Participants will be stratified into cohorts by disease type and biomarker status (TMB^{hi}/GEP^{hi}; TMB^{hi}/GEP^{lo} TMB^{lo}/GEP^{hi}; $TMB^{lo}GEP^{lo}$)

Stage I –Sites will order specimen kits per Section 15.2 one week prior to registration. Sites will register participants to Step 1 registration. Sites must submit specimens for biomarker testing via the SWOG Specimen Tracking System within one day after Step 1 registration. Sites will register participants to Step 2 registration. Participants will begin treatment prior to availability of results. Participants will be assigned to their biomarker cohort retrospectively. Sites will be informed when the trial progresses to Stage II.



Stage II – Sites will order specimen kits per Section 15.2 one week prior to registration. Sites will register participants to Step 1 registration. Sites will submit specimens for biomarker testing via the SWOG Specimen Tracking System within one day after Step 1 registration. Sites will receive the biomarker results and will register participants to Step 2 registration only if a slot in an available biomarker cohort is available. Sites will be informed when the trial progresses to Stage II.



EA5162
Navigator - Ashton x3611

MENU

Schema



Cycle = 3 weeks (21 days)
Accrual = 20 patients

1. Until disease progression or unacceptable toxicities.
2. Restaging scans every 2 cycles (6 weeks).
3. Patients will be followed for 5 years from registration.

The primary endpoint is best objective response per RECIST 1.1, with confirmation of response required.

Schema



* Patients with newly diagnosed advanced unresectable or metastatic HER2 negative gastric, GEJ, esophageal adenocarcinoma

** Stratification: Tumor location (gastric vs GEJ vs esophagus); Measurable disease vs not; planned nivo use vs not; PD-L1 CPS ≥ 5 vs < 5.

Patients will be treated using 14-day cycles until disease progression or discontinuation of treatment for other reasons (e.g. unacceptable adverse events, withdrawal, etc.); oxaliplatin will be given up to 12 cycles.

S2010
Navigator - Erica x3626

MENU



URCC 19185
Navigator - Erica x3626

MENU

Study Schema



SCHEMA



A For guidance on Investigator's Choice of Standard of Care, see Section 7.2.

S2200
Navigator - Carrie x3621

MENU